Brown Advisory Inc. Increases Holdings in Elevance Health, Inc. $ELV

Brown Advisory Inc. lifted its position in shares of Elevance Health, Inc. (NYSE:ELV) by 4.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 499,939 shares of the company’s stock after buying an additional 19,760 shares during the period. Brown Advisory Inc.’s holdings in Elevance Health were worth $175,254,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Rossby Financial LCC boosted its stake in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares in the last quarter. J.Safra Asset Management Corp purchased a new stake in shares of Elevance Health during the 4th quarter worth approximately $32,000. ORG Partners LLC boosted its stake in shares of Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Elevance Health during the 4th quarter worth approximately $38,000. Finally, Dorato Capital Management purchased a new stake in Elevance Health in the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 1.1%

Shares of ELV opened at $403.74 on Friday. The stock has a fifty day moving average of $366.62 and a two-hundred day moving average of $344.86. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The company has a market capitalization of $87.68 billion, a PE ratio of 17.17, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $426.98.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.Elevance Health’s revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts forecast that Elevance Health, Inc. will post 26.93 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be issued a $1.72 dividend. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s payout ratio is 29.26%.

Analyst Ratings Changes

A number of research firms recently issued reports on ELV. JPMorgan Chase & Co. upped their target price on Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Mizuho upped their target price on Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. UBS Group upped their target price on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Citigroup raised Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings raised Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Fourteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $416.11.

Insiders Place Their Bets

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.34% of the company’s stock.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.